Ataluren (Translarna®)

Ataluren (Translarna®)

Status

Phase |||

Therapeutic Approach

Restoring or Replacing Dystrophin

Duchenne can be caused by a number of genetic mutations (changes). Ataluren (Translarna®) is for use in patients with “nonsense mutations” in the dystrophin gene, which prematurely stop the production of a normal dystrophin protein and lead to a shortened and nonfunctional dystrophin protein. Translarna works in these patients by enabling the protein-making apparatus in cells to move past the nonsense mutation, allowing the cells to produce a functional dystrophin protein.

Status

In August 2014 Translarna received marketing authorization in the European Union for the treatment of nonsense mutation Duchenne in ambulatory patients aged five years and older, representing the first-ever treatment approved for the underlying cause of the disease.

PTC is expanding commercial access to Translarna across Europe, the Middle East, Latin America, and Asia Pacific.

PTC has engaged in dialogue with the US Food and Drug Administration regarding a path forward to bring Translarna to patients in the US.

A Phase 3 study is currently actively recruiting around the world. Two trials to study dystrophin levels in nonsense mutation patients (both Translarna-treated and untreated) also began recruiting in 2019.

Sponsor

This program is sponsored by PTC Therapeutics.

Related Studies

ACTIVELY RECRUITING
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NOT YET RECRUITING
A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
ONGOING
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy
OPEN LABEL EXTENSION
Study of Ataluren in Previously Treated Participants

Media Library

JUNE 2019

PTC Therapeutics Presents at the PPMD 2019 Annual Conference

JANUARY 2019

Webinar: Translarna® (ataluren) Development Update

On January 16, 2019, PTC Therapeutics joined Parent Project Muscular Dystrophy for a webinar update to provide the community with an overview of the Translarna development program with a focus on clinical trials that are recruiting.
JUNE 2018

PTC Therapeutics Presents at the PPMD 2018 Annual Conference

AUG 2016

Webinar: PTC Therapeutics Provides Regulatory Update on Translarna

On August 1, 2016, PPMD hosted a webinar with PTC Therapeutics to discuss the latest news regarding Translarna.

Join Our Mailing List